Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,639.50GBp
24 Feb 2017
Change (% chg)

7.00 (+0.43%)
Prev Close
1,632.50
Open
1,631.50
Day's High
1,642.00
Day's Low
1,619.00
Volume
6,254,356
Avg. Vol
9,430,755
52-wk High
1,745.56
52-wk Low
1,355.00

Latest Key Developments (Source: Significant Developments)

GSK reports positive results in study for controlled asthma
Thursday, 23 Feb 2017 04:46am EST 

GlaxoSmithKline Plc : Positive results for Relvar Ellipta lung function study in patients with well-controlled asthma . Patients randomised to FF/VI taken once-daily maintained lung function versus those randomised to twice-daily FP/SAL, meeting study's primary endpoint . GSK now intends to submit this data to European Medicines Agency (EMA) .Incidences of on-treatment serious adverse events and adverse events of special interest were consistent with known safety profile of FF/VI,.  Full Article

GSK announces positive final stage results for two-drug HIV treatment
Tuesday, 14 Feb 2017 02:00am EST 

GlaxoSmithKline Plc : VIIV phase III results dolutegravir & rilpivirine . Announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment . In sword studies, two-drug regimen showed comparable efficacy to three- or four-drug regimens in virologically suppressed patients . Headline results were announced in December 2016 .Use of dolutegravir and rilpivirine as a two-drug regimen for hiv-1 maintenance therapy is investigational and not approved anywhere in world.  Full Article

ViiV Healthcare announces positive phase III results for two-drug regimen of Dolutegravir and Rilpivirine
Monday, 13 Feb 2017 06:55pm EST 

: ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment . ViiV Healthcare - in SWORD studies, two-drug regimen showed comparable efficacy to three- or four-drug regimens in virologically suppressed patients . ViiV Healthcare - planning regulatory submissions for two-drug regimen as a single tablet in 2017 Further company coverage: [GSK.L] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

New GSK CEO likely to give strategy update in H2 2017
Wednesday, 8 Feb 2017 07:45am EST 

Outgoing GlaxoSmithKline CEO Andrew Witty told reporters: 2017 outlook "very much" in line with market consensus . Lot of common ground with Trump on FDA regulatory reform but need to ensure safety . Accelerated drug approvals would give room for lowering drug prices . Shame if EMA moves from London because will cause disruption . Would be wise for UK to get significant mutual recognition with EMA on drug approvals . New CEO Emma Walmsley likely to update investors on strategy in H2 2017 Further company coverage: [GSK.L] (Reporting by UK bureau) ((uk.online@reuters.com;)).  Full Article

GSK says launched flonase sensimist allergy relief nationwide
Wednesday, 8 Feb 2017 07:00am EST 

GlaxoSmithKline PLC :GSK Consumer Healthcare - announced nationwide launch of flonase sensimist allergy relief.  Full Article

Pernix Therapeutics provides update on arbitration
Friday, 3 Feb 2017 08:00am EST 

Pernix Therapeutics Holdings Inc : Pernix therapeutics provides update on arbitration . Pernix therapeutics - pernix and gsk had been in arbitration regarding claims related to treximet asset purchase agreement and supply agreement . Is reviewing opinions, including amount of interest, and intends to work with gsk to conclude matter . Tribunal also denied pernix's claim that gsk breached its obligations under supply agreement . Pernix therapeutics - on jan 31, , arbitration tribunal issued opinions in favor of gsk, awarding it damages, fees in amount of about $35 million, plus interes .Pernix therapeutics holdings - pernix has already paid to gsk, or into an escrow account, an aggregate of $16.5 million, which will offset total award.  Full Article

EMA recommends approval of two biosimilars from Amgen
Friday, 27 Jan 2017 07:21am EST 

European Medicines Agency : EU Medicines Agency recommendations for January 2017 . EU Medicines Agency recommends approval of Amgen's Amgevita and Solymbic, both containing adalimumab . EU Medicines Agency recommends approval of Tadalafil Lilly for treatment of erectile dysfunction and signs, symptoms of benign prostatic hyperplasia . EU Medicines Agency's CHMP offers positive opinion for Rolufta for the treatment of chronic obstructive pulmonary disease .EU Medicines Agency - Jylamvo (methotrexate) received a positive opinion for the treatment of rheumatological disorders and psoriasis, and for maintenance treatment of ALL.  Full Article

GlaxoSmithKline appoints Luke Miels President, Global Pharma
Thursday, 19 Jan 2017 02:09am EST 

Glaxosmithkline Plc : Luke Miels appointed president, global pharmaceuticals, gsk .Luke is currently executive vice president (evp) of astrazeneca's european business.  Full Article

GSK's pharmaceuticals president Abbas Hussain to leave in 2017
Thursday, 19 Jan 2017 02:05am EST 

Glaxosmithkline Plc :Abbas hussain, president, global pharmaceuticals has decided to leave company. He has agreed with gsk that he will leave company later this year.  Full Article

GSK's Viiv announces positive results from initial HIV phase III studies
Tuesday, 20 Dec 2016 02:00am EST 

Glaxosmithkline Plc : First phase iii studies to show efficacy of two-drug regimen as maintenance therapy .Viiv healthcare announces positive results from first phase iii studies of two-drug hiv treatment regimen.  Full Article

More From Around the Web

BRIEF-GSK reports positive results in study for controlled asthma

* Positive results for Relvar Ellipta lung function study in patients with well-controlled asthma